This study establishes that changes in lymphocyte subsets, especially the CD4+/CD8+ ratio, are significantly associated with clinical features, treatment response, and survival outcomes, highlighting its prognostic value in DLBCL. Here, CD8A is linked to diffuse large B-cell lymphoma.